106 related articles for article (PubMed ID: 19426700)
21. Induction of rat intestinal P-glycoprotein by spironolactone and its effect on absorption of orally administered digoxin.
Ghanem CI; Gómez PC; Arana MC; Perassolo M; Delli Carpini G; Luquita MG; Veggi LM; Catania VA; Bengochea LA; Mottino AD
J Pharmacol Exp Ther; 2006 Sep; 318(3):1146-52. PubMed ID: 16740618
[TBL] [Abstract][Full Text] [Related]
22. Effect of recombinant interleukin-2 pretreatment on oral and intravenous digoxin pharmacokinetics and P-glycoprotein activity in mice.
Castagne V; Bonhomme-Faivre L; Urien S; Ben Reguiga M; Soursac M; Gimenez F; Farinotti R
Drug Metab Dispos; 2004 Feb; 32(2):168-71. PubMed ID: 14744937
[TBL] [Abstract][Full Text] [Related]
23. Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol.
Schwarz UI; Hanso H; Oertel R; Miehlke S; Kuhlisch E; Glaeser H; Hitzl M; Dresser GK; Kim RB; Kirch W
Clin Pharmacol Ther; 2007 May; 81(5):669-78. PubMed ID: 17392718
[TBL] [Abstract][Full Text] [Related]
24. Intestinal perfusion with mesenteric blood sampling in wild-type and knockout mice: evaluation of a novel tool in biopharmaceutical drug profiling.
Mols R; Brouwers J; Schinkel AH; Annaert P; Augustijns P
Drug Metab Dispos; 2009 Jun; 37(6):1334-7. PubMed ID: 19273528
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics and neutrophil toxicity of paclitaxel orally administered in mice with recombinant interleukin-2.
Jamois C; Comets E; Mentré F; Marion S; Farinotti R; Bonhomme-Faivre L
Cancer Chemother Pharmacol; 2005 Jan; 55(1):61-71. PubMed ID: 15378273
[TBL] [Abstract][Full Text] [Related]
26. The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions.
Polli JW; Humphreys JE; Harmon KA; Castellino S; O'Mara MJ; Olson KL; John-Williams LS; Koch KM; Serabjit-Singh CJ
Drug Metab Dispos; 2008 Apr; 36(4):695-701. PubMed ID: 18216274
[TBL] [Abstract][Full Text] [Related]
27. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833.
Mayer U; Wagenaar E; Dorobek B; Beijnen JH; Borst P; Schinkel AH
J Clin Invest; 1997 Nov; 100(10):2430-6. PubMed ID: 9366556
[TBL] [Abstract][Full Text] [Related]
28. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure.
Smit JW; Huisman MT; van Tellingen O; Wiltshire HR; Schinkel AH
J Clin Invest; 1999 Nov; 104(10):1441-7. PubMed ID: 10562306
[TBL] [Abstract][Full Text] [Related]
29. Characterization of gastrointestinal absorption of digoxin involving influx and efflux transporter in rats: application of mdr1a knockout (-/-) rats into absorption study of multiple transporter substrate.
Suzuki M; Komura H; Yoshikawa T; Enya S; Nagao A; Takubo H; Kogayu M
Xenobiotica; 2014 Nov; 44(11):1039-45. PubMed ID: 24839994
[TBL] [Abstract][Full Text] [Related]
30. P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain and blood disposition of the mTOR Inhibitor everolimus (Afinitor) in mice.
Tang SC; Sparidans RW; Cheung KL; Fukami T; Durmus S; Wagenaar E; Yokoi T; van Vlijmen BJ; Beijnen JH; Schinkel AH
Clin Cancer Res; 2014 Jun; 20(12):3133-45. PubMed ID: 24727322
[TBL] [Abstract][Full Text] [Related]
31. Differential involvement of multidrug resistance-associated protein 1 and P-glycoprotein in tissue distribution and excretion of grepafloxacin in mice.
Sasabe H; Kato Y; Suzuki T; Itose M; Miyamoto G; Sugiyama Y
J Pharmacol Exp Ther; 2004 Aug; 310(2):648-55. PubMed ID: 15131241
[TBL] [Abstract][Full Text] [Related]
32. Enhanced bioavailability of etoposide after oral or intravenous administration of etoposide with kaempferol in rats.
Li C; Li X; Choi JS
Arch Pharm Res; 2009 Jan; 32(1):133-8. PubMed ID: 19183886
[TBL] [Abstract][Full Text] [Related]
33. Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer.
Pajic M; Iyer JK; Kersbergen A; van der Burg E; Nygren AO; Jonkers J; Borst P; Rottenberg S
Cancer Res; 2009 Aug; 69(16):6396-404. PubMed ID: 19654309
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic interaction between verapamil and everolimus in healthy subjects.
Kovarik JM; Beyer D; Bizot MN; Jiang Q; Allison MJ; Schmouder RL
Br J Clin Pharmacol; 2005 Oct; 60(4):434-7. PubMed ID: 16187976
[TBL] [Abstract][Full Text] [Related]
35. Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: a case series.
Lunardi G; Armirotti A; Nicodemo M; Cavallini L; Damonte G; Vannozzi MO; Venturini M
Clin Ther; 2009 Aug; 31(8):1812-9. PubMed ID: 19808140
[TBL] [Abstract][Full Text] [Related]
36. Everolimus attenuates neointimal hyperplasia in cultured human saphenous vein grafts.
Semsroth S; Stigler RG; Bernecker OY; Ruttmann-Ulmer E; Troppmair J; Macfelda K; Bonatti JO; Laufer G
Eur J Cardiothorac Surg; 2009 Mar; 35(3):515-20. PubMed ID: 19167904
[TBL] [Abstract][Full Text] [Related]
37. Oral everolimus inhibits neointimal proliferation in prosthetic pulmonary valved stents in pigs.
Kuehne T; Pietzner K; Lehmkuhl HB; Gelernter D; Peters B; Krueger JJ; Meinus C; Klimes K; Brinkert F; Ewert P; Berger F
J Heart Valve Dis; 2008 Jul; 17(4):465-72. PubMed ID: 18751477
[TBL] [Abstract][Full Text] [Related]
38. P-glycoprotein effects of cyclic urea HIV protease inhibitor DMP 323 in competitional absorption studies.
Richter M; Gyémánt N; Molnár J; Hilgeroth A
Arch Pharm (Weinheim); 2006 Nov; 339(11):625-8. PubMed ID: 17048292
[TBL] [Abstract][Full Text] [Related]
39. Regional differences in capillary density, perfusion rate, and P-glycoprotein activity: a quantitative analysis of regional drug exposure in the brain.
Zhao R; Pollack GM
Biochem Pharmacol; 2009 Oct; 78(8):1052-9. PubMed ID: 19523457
[TBL] [Abstract][Full Text] [Related]
40. Effect of lapatinib on oral digoxin absorption in patients.
Koch KM; Smith DA; Botbyl J; Arya N; Briley LP; Cartee L; White JH; Beyer J; Dar MM; Chung HC; Chu Q; Bang YJ
Clin Pharmacol Drug Dev; 2015 Nov; 4(6):449-53. PubMed ID: 27137717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
